Cadila Healthcare gets EIR from USFDA for its Ahmedabad facility

The company's topical manufacturing facility at Ahmedabad has received an EIR from the United States Food and Drug Administration (USFDA) signifying the successful closure of the audit, Cadila Healthcare said in a filing to the BSE.

PTI

February 10, 2020 / 15:45 IST

26 Aug, 2025 12:21

Volume

Todays L/H

Drug firm Cadila Healthcare on Monday said it has received establishment inspection report (EIR) from the US health regulator after inspection of its Ahmedabad facility.

The company's topical manufacturing facility at Ahmedabad has received an EIR from the United States Food and Drug Administration (USFDA) signifying the successful closure of the audit, Cadila Healthcare said in a filing to the BSE.

The facility completed the USFDA audit from December 16 to 20, 2019 with zero 483 observations, it added.

Shares of Cadila Healthcare were trading 0.60 percent higher at Rs 276.95 per scrip on the BSE.

PTI

first published: Feb 10, 2020 03:40 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

Al Edge Newsletter On Saturdays

Find the best of Al News in one place, specially curated for you every weekend.
MC Tech 3 Newsletter Daily-Weekdays

Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347